Cargando…

A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies

The calcium channel blocker and antiarrhythmic agent verapamil is recommended by the FDA for drug–drug interaction (DDI) studies as a moderate clinical CYP3A4 index inhibitor and as a clinical Pgp inhibitor. The purpose of the presented work was to develop a mechanistic whole-body physiologically ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanke, Nina, Türk, Denise, Selzer, Dominik, Wiebe, Sabrina, Fernandez, Éric, Stopfer, Peter, Nock, Valerie, Lehr, Thorsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355632/ https://www.ncbi.nlm.nih.gov/pubmed/32560124 http://dx.doi.org/10.3390/pharmaceutics12060556

Ejemplares similares

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug–Drug–Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals
por: Hanke, Nina, et al.
Publicado: (2020)

Inherent adriamycin resistance in a murine tumour line: circumvention with verapamil and norverapamil.
por: Merry, S., et al.
Publicado: (1989)

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions
por: Britz, Hannah, et al.
Publicado: (2020)

Significant impact of time-of-day variation on metformin pharmacokinetics
por: Türk, Denise, et al.
Publicado: (2023)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
por: Fuhr, Laura Maria, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
por: Marok, Fatima Zahra, et al.
Publicado: (2021)

A Physiologically-Based Pharmacokinetic Model of Trimethoprim for MATE1, OCT1, OCT2, and CYP2C8 Drug–Drug–Gene Interaction Predictions
por: Türk, Denise, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
por: Hanke, Nina, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions
por: Rüdesheim, Simeon, et al.
Publicado: (2020)

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling
por: Fuhr, Laura Maria, et al.
Publicado: (2022)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug–Drug Interaction Perpetrators
por: Marok, Fatima Zahra, et al.
Publicado: (2023)

Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine
por: Wiebe, Sabrina T., et al.
Publicado: (2020)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole
por: Türk, Denise, et al.
Publicado: (2019)

Prediction of Drug–Drug–Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling
por: Kovar, Christina, et al.
Publicado: (2022)

Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups
por: Rüdesheim, Simeon, et al.
Publicado: (2022)

Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically‐Based Pharmacokinetic Modeling
por: Wojtyniak, Jan‐Georg, et al.
Publicado: (2020)

Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients
por: Kovar, Lukas, et al.
Publicado: (2020)

Influence of verapamil on the pharmacokinetics of oridonin in rats
por: Liu, Jing, et al.
Publicado: (2019)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network
por: Feick, Denise, et al.
Publicado: (2023)

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates
por: Kovar, Lukas, et al.
Publicado: (2020)

Enantioselectivity in Drug Pharmacokinetics and Toxicity: Pharmacological Relevance and Analytical Methods
por: Coelho, Maria Miguel, et al.
Publicado: (2021)

The enantioselective enhancing effect and mechanistic insights of chiral enhancers in transdermal drug delivery
por: Zhang, Yang, et al.
Publicado: (2023)

Verapamil as an Adjuvant Treatment for Drug-Resistant Epilepsy
por: Lakshmikanthcharan, S., et al.
Publicado: (2018)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban
por: Kim, Minsoo, et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Modeling to Describe the CYP2D6 Activity Score-Dependent Metabolism of Paroxetine, Atomoxetine and Risperidone
por: Rüdesheim, Simeon, et al.
Publicado: (2022)

Unravelling the complex drug–drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein
por: Ledwitch, Kaitlyn V., et al.
Publicado: (2016)

External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease
por: Schräpel, Christina, et al.
Publicado: (2021)

Phase I and pharmacokinetic study of D-verapamil and doxorubicin.
por: Bissett, D., et al.
Publicado: (1991)

Pharmacokinetics of doxorubicin co-administered with high-dose verapamil.
por: Gigante, M., et al.
Publicado: (1995)

Effect of verapamil on the pharmacokinetics of hydroxycamptothecin and its potential mechanism
por: Xing, Hua, et al.
Publicado: (2020)

Pharmacokinetic Interaction between Metformin and Verapamil in Rats: Inhibition of the OCT2-Mediated Renal Excretion of Metformin by Verapamil
por: Han, Seung Yon, et al.
Publicado: (2020)

Physiologically‐Based Pharmacokinetic Models for CYP1A2 Drug–Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam
por: Britz, Hannah, et al.
Publicado: (2019)

Enantioselective Drug Recognition by Drug Transporters
por: Uwai, Yuichi
Publicado: (2018)

Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys
por: Lu, Dan, et al.
Publicado: (2014)

Influence of verapamil on the pharmacokinetics of rotundic acid in rats and its potential mechanism
por: Shang, Haihua, et al.
Publicado: (2021)

Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis
por: Fuhr, Laura Maria, et al.
Publicado: (2020)

Verapamil in Diabetes
por: Poudel, Resham Raj, et al.
Publicado: (2017)

Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
por: Scheithauer, W., et al.
Publicado: (1993)

Cannot write session to /tmp/vufind_sessions/sess_pamhdctusbi0idb84te00cr6mi